Personalized cancer medicine and the future of pathology

In February 2011, a group of pathologists from different departments in Europe met in Zurich, Switzerland, to discuss opportunities and challenges for pathology in the era of personalized medicine. The major topics of the meeting were assessment of the role of pathology in personalized medicine, its future profile among other biomedical disciplines with an interest in personalized medicine as well as the evolution of companion diagnostics. The relevance of novel technologies for genome analysis in clinical practice was discussed. The participants recognize that there should be more initiatives taken by the pathology community in companion diagnostics and in the emerging field of next-generation sequencing and whole genome analysis. The common view of the participants was that the pathology community has to be mobilized for stronger engagement in the future of personalized medicine. Pathologists should be aware of the challenges and the analytical opportunities of the new technologies. Challenges of clinical trial design as well as insurance and reimbursement questions were addressed. The pathology community has the responsibility to lead medical colleagues into embracing this new area of genomic medicine. Without this effort, the discipline of pathology risks losing its key position in molecular tissue diagnostics.

[1]  T. Stricker,et al.  Molecular profiling of cancer--the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic. , 2011, Seminars in oncology.

[2]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[3]  M. Heinrich,et al.  Gastrointestinal stromal tumour , 2007, The Lancet.

[4]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[5]  K. Kerr.  Personalized medicine for lung cancer: new challenges for pathology , 2012, Histopathology.

[6]  Holger Moch,et al.  Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost–effectiveness analysis of different predictive assay strategies , 2010, Breast Cancer Research and Treatment.

[7]  J. M. Crawford,et al.  A national agenda for the future of pathology in personalized medicine: report of the proceedings of a meeting at the Banbury Conference Center on genome-era pathology, precision diagnostics, and preemptive care: a stakeholder summit. , 2011, American journal of clinical pathology.

[8]  G. Hortobagyi.  Trastuzumab in the treatment of breast cancer. , 2005, The New England journal of medicine.

[9]  Vipul Kashyap,et al.  The Translational Medicine Ontology and Knowledge Base: driving personalized medicine by bridging the gap between bench and bedside , 2011, J. Biomed. Semant..

[10]  H. Moch,et al.  KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective , 2011, Clinical Cancer Research.

[11]  E. Gabrielson,et al.  Functional Genomics, Gene Arrays, and the Future of Pathology , 2001, Modern Pathology.

[12]  P. Jares,et al.  KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program , 2008, Virchows Archiv.

[13]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[14]  W. Hahn,et al.  Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. , 2011, Cancer discovery.

[15]  Michael Thomas,et al.  Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  Manfred Dietel,et al.  Personalized medicine and development of targeted therapies: the upcoming challenge for diagnostic molecular pathology. A review , 2006, Virchows Archiv.

[17]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[18]  S. Dacic,et al.  Genomic pathology: challenges for implementation. , 2011, Archives of pathology & laboratory medicine.

[19]  S. Gillen.  Getting personal. , 2012, Mental health today.

[20]  T. Szucs,et al.  Cost Effectiveness of Cytotoxic and Targeted Therapy for Metastatic Breast Cancer , 2012, PharmacoEconomics.

[21]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[22]  Peter Bühlmann,et al.  Mining Tissue Microarray Data to Uncover Combinations of Biomarker Expression Patterns that Improve Intermediate Staging and Grading of Clear Cell Renal Cell Cancer , 2009, Clinical Cancer Research.

[23]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[24]  Ken Jones,et al.  Getting Personal , 1995 .

[25]  A. Jimeno,et al.  KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  P. Kulesza,et al.  Emerging concepts in the pathology and molecular biology of advanced non-small cell lung cancer. , 2011, American journal of clinical pathology.

[27]  Francesca Demichelis,et al.  Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma , 2010, Nature Medicine.

[28]  The Association for Molecular Pathology's approach to supporting a global agenda to embrace personalized genomic medicine. , 2011, Journal of Molecular Diagnostics.

[29]  F.A.M. Bordonaba,et al.  Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer , 2009 .

[30]  A. Marchetti,et al.  Recommendations for mutational analysis of EGFR in lung carcinoma. , 2010, Pathologica.

[31]  P. Pandolfi,et al.  Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. , 2008, The Journal of clinical investigation.

[32]  J. Orenstein,et al.  Revolution in lung cancer: new challenges for the surgical pathologist. , 2012, Archives of pathology & laboratory medicine.

[33]  Sabine Tejpar,et al.  Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[35]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[36]  S. Salzberg,et al.  Do-it-yourself genetic testing , 2010, Genome Biology.

[37]  L. Tanoue.  Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR , 2011 .